GlassScriptPhysician profile
Yanelys Gil
NPI 1164910444
$4,276.70
in general payments reported to CMS, 2019-2025
22 companies · $1,282 in 2025
The $1,282 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,140 · 2022: $500 · 2023: $235 · 2024: $1,120 · 2025: $1,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,156.91 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $697.11 | 2021 | |
| Scilex Pharmaceuticals INC. | $467.51 | 2024-2025 | |
| Lilly USA, LLC | $278.96 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $256.71 | 2024-2025 | |
| Amgen INC. | $196.32 | 2021-2022 | |
| Fisher & Paykel Healthcare INC | $150.78 | 2023 | Fisher & Paykel Healthcare |
| Neurelis, INC. | $138.11 | 2024-2025 | Valtoco |
| Upsher-Smith Laboratories LLC | $132.52 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $126.64 | 2021-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $97.43 | 2025 | Hyqvia |
| Allergan, INC. | $85.74 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $85.01 | 2024-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $71.56 | 2024-2025 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $69.14 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $63.54 | 2025 | Xeomin, Inbrija, Ampyra |
| Ucb, INC. | $46.68 | 2024 | Briviact |
| Boston Scientific Corporation | $45.72 | 2025 | Watchman Flx, Vercise |
| Mallinckrodt Hospital Products INC. | $30.51 | 2025 | Acthar |
| Janssen Biotech, INC. | $30.17 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $25.08 | 2024 | Rexulti |
| Octapharma USA, INC. | $24.55 | 2025 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanelys Gil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.